MicroRNA-9 promotes tumorigenesis and mediates sensitivity to XXXX in primary @entity43 cells.

@entity1 @entity43 @entity5 @entity17309 @entity900 @entity27165 @entity902 @entity3373
UNASSIGNED: MicroRNAs play critical roles in regulating @entity5 occurrence and drug @entity43 . This study aimed to investigate the key members of MicroRNAs (miRNAs) involved in modulating @entity5 initiation and drug resistance in primary @entity43 cells. An in vitro assay based on @entity5 clonal formation was established to evaluate tumorigenicity and @entity900 sensitivity. By performing real-time polymerase chain reaction, we examined the expression of nine microRNAs associated with the pathology of @entity43 in primary @entity43 cells, which were surgically resected from 46 @entity1 with distinct sensitivity to @entity902 -based chemotherapy. MiR-9, @entity3373 , and @entity27165 were expressed significantly higher in drug-sensitive @entity1 (n   =   26) than in drug-resistant ones (n   =   20), while higher @entity17309 expression was found in resistant @entity1 (p   <   0.05). In addition, @entity5 cells from drug sensitive @entity1 were more tumorigenic than those of drug resistance (p   =   0.0013). @entity900 treatment led to a sharp decrease of clonal formation of drug-sensitive cells but showed slight effects on drug resistant cells. Specific anti-miRs were then employed to downregulate the expression of microRNAs in primary @entity5 cells. Inhibition of miR-9 resulted in decreased clonal formation and sensitivity to @entity900 , while the knockdown of other three microRNAs did not show any influence in tumorigenesis and drug sensitivity. In conclusion, this study showed that in primary @entity43 cells, high expression of miR-9 was associated with enhanced tumorigenesis and increased sensitivity of the @entity5 cells to @entity900 treatment.
